Valion Bio (VIBO) Q2 2026 earnings summary

Executive summary

• Transitioned to a late-stage biopharma company focused on Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS) and oncology indications, with Fast Track and Orphan Drug designations from the FDA.

• Acquired Scorpius Holdings' CDMO assets, vertically integrating manufacturing and expanding into contract services via subsidiary Velocity Bioworks.

• Appointed Michael K. Handley as CEO and Melinda Lackey as General Counsel in 2026.

• Rebranded as Valion Bio and changed ticker to VBIO in April 2026.

Financial highlights

• Net loss for Q2 2026 was $7.1M, up from $1.9M in Q2 2025; six-month net loss was $13.3M, up from $3.4M year-over-year.

• Operating expenses rose to $6.4M for Q2 2026 (from $1.7M) and $12.1M for the first half (from $3.1M), driven by CDMO operations and R&D investments.

• Cash and cash equivalents were $2.1M as of June 30, 2026, down from $12.6M at year-end 2025.

• Accumulated deficit reached $66.5M as of June 30, 2026.

Outlook and guidance

• Expects continued significant operating losses as development and regulatory activities for Entolimod and Entolasta progress.

• Anticipates need for substantial additional financing to fund clinical trials, operations, and commercialization.

• No near-term revenue expected from CDMO business as facilities are still being qualified.